These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30905295)

  • 41. Application of CRISPR/Cas System in the Metabolic Engineering of Small Molecules.
    Singh R; Chandel S; Ghosh A; Dey D; Chakravarti R; Roy S; Ravichandiran V; Ghosh D
    Mol Biotechnol; 2021 Jun; 63(6):459-476. PubMed ID: 33774733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR-Cas systems: beyond adaptive immunity.
    Westra ER; Buckling A; Fineran PC
    Nat Rev Microbiol; 2014 May; 12(5):317-26. PubMed ID: 24704746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein Inhibitors of CRISPR-Cas9.
    Bondy-Denomy J
    ACS Chem Biol; 2018 Feb; 13(2):417-423. PubMed ID: 29251498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches.
    Ahmed MZ; Badani P; Reddy R; Mishra G
    J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-CasΦ from huge phages is a hypercompact genome editor.
    Pausch P; Al-Shayeb B; Bisom-Rapp E; Tsuchida CA; Li Z; Cress BF; Knott GJ; Jacobsen SE; Banfield JF; Doudna JA
    Science; 2020 Jul; 369(6501):333-337. PubMed ID: 32675376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Variability in the durability of CRISPR-Cas immunity.
    Chabas H; Nicot A; Meaden S; Westra ER; Tremblay DM; Pradier L; Lion S; Moineau S; Gandon S
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180097. PubMed ID: 30905283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
    Tapscott T; Guarnieri MT; Henard CA
    Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frontiers in CRISPR.
    Weidmann AG
    ACS Chem Biol; 2018 Feb; 13(2):296-304. PubMed ID: 29448764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Editing
    Dehshahri A; Biagioni A; Bayat H; Lee EHC; Hashemabadi M; Fekri HS; Zarrabi A; Mohammadinejad R; Kumar AP
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAMERS-B: CRISPR/Cpf1 assisted multiple-genes editing and regulation system for Bacillus subtilis.
    Wu Y; Liu Y; Lv X; Li J; Du G; Liu L
    Biotechnol Bioeng; 2020 Jun; 117(6):1817-1825. PubMed ID: 32129468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.
    Boucher P; Cui X; Curiel DT
    J Control Release; 2020 Nov; 327():788-800. PubMed ID: 32891680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity.
    Wang YM; Wang HZ; Jian YZ; Luo ZT; Shao HW; Zhang WF
    Hum Gene Ther; 2022 Apr; 33(7-8):358-370. PubMed ID: 34963339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
    Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
    Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR/Cas-based genome engineering in natural product discovery.
    Tong Y; Weber T; Lee SY
    Nat Prod Rep; 2019 Sep; 36(9):1262-1280. PubMed ID: 30548045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protospacer-Adjacent Motif Specificity during Clostridioides difficile Type I-B CRISPR-Cas Interference and Adaptation.
    Maikova A; Boudry P; Shiriaeva A; Vasileva A; Boutserin A; Medvedeva S; Semenova E; Severinov K; Soutourina O
    mBio; 2021 Aug; 12(4):e0213621. PubMed ID: 34425703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.
    Marino ND; Pinilla-Redondo R; Csörgő B; Bondy-Denomy J
    Nat Methods; 2020 May; 17(5):471-479. PubMed ID: 32203383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meeting Report: German Genetics Society-Genome Editing with CRISPR.
    Maier LK; Marchfelder A; Randau L
    Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989
    [No Abstract]   [Full Text] [Related]  

  • 59. CRISPR/CAS9 Technologies.
    Williams BO; Warman ML
    J Bone Miner Res; 2017 May; 32(5):883-888. PubMed ID: 28230927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delivery of CRISPR-Cas systems using phage-based vectors.
    Fage C; Lemire N; Moineau S
    Curr Opin Biotechnol; 2021 Apr; 68():174-180. PubMed ID: 33360715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.